Eribulin mesylate (halichondrin B Analog E7389) in platinum-resistant and platinum-sensitive ovarian cancer: a two-cohort, phase II study

Por Hensley, Martee L., Kravetz, Sara, Jia, Xiaoyu, Iasonos, Alexia, Tew, William, Pereira, Lauren, Sabbatini, Paul, Whalen, Christin, Aghajanian, Carol A., Zarwan, Corinne, Berlin, Suzanne
Publicado em 2011

A Phase 1 trial of the PARP inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cance...

Por Liu, Joyce F., Tolaney, Sara M., Birrer, Michael, Fleming, Gini F., Buss, Mary K., Dahlberg, Suzanne E., Lee, Hang, Whalen, Christin, Tyburski, Karin, Winer, Eric, Ivy, Percy, Matulonis, Ursula A.
Publicado em 2013

Cediranib, an Oral Inhibitor of Vascular Endothelial Growth Factor Receptor Kinases, Is an Active Drug in Recurrent Epithelial Ovarian, Fallopian Tube, and Peritoneal Cancer

Por Matulonis, Ursula A., Berlin, Suzanne, Ivy, Percy, Tyburski, Karin, Krasner, Carolyn, Zarwan, Corrine, Berkenblit, Anna, Campos, Susana, Horowitz, Neil, Cannistra, Stephen A., Lee, Hang, Lee, Julie, Roche, Maria, Hill, Margaret, Whalen, Christin, Sullivan, Laura, Tran, Chau, Humphreys, Benjamin D., Penson, Richard T.
Publicado em 2009

A randomized phase 2 study of combination cediranib and olaparib versus olaparib alone as recurrence therapy in platinum-sensitive ovarian cancer

Por Liu, Joyce F., Barry, William T., Birrer, Michael, Lee, Jung-Min, Buckanovich, Ronald J., Fleming, Gini F., Rimel, BJ, Buss, Mary K., Nattam, Sreenivasa, Hurteau, Jean, Luo, Weixiu, Quy, Philippa, Whalen, Christin, Obermayer, Lisa, Lee, Hang, Winer, Eric P., Kohn, Elise C., Ivy, S. Percy, Matulonis, Ursula A.
Publicado no Lancet Oncol (2014)